- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06333652
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
April 19, 2024 updated by: Maria Lourdes Gonzalez Suarez, Mayo Clinic
Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
14
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Minnesota
-
Contact:
- Maria L. Gonzalez Suarez, MD,PhD
- Phone Number: 507-284-4083
- Email: gonzalezsuarez.maria@mayo.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Individuals with < 34 0/7 weeks of gestation.
- Individuals with severe preeclampsia or HELLP features.
Exclusion Criteria:
- Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
- Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Revulizumab Treatment
Subjects will receive an single-dose infusion of Ravulizumab.
|
Intravenous infusion 100 mg/ml
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alternative Complement Pathway Biomarkers at time of delivery
Time Frame: Baseline
|
Concentration in serum of biomarkers: sMAC, Bb, and C5 at time of delivery
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy duration
Time Frame: Approximately 40 weeks
|
Length of pregnancy measured in number of weeks.
|
Approximately 40 weeks
|
Clinical biomarkers of severe features of preeclampsia and HELLP syndrome
Time Frame: 72 hours after Ravulizumab infusion
|
Concentration of clinical biomarkers in serum: creatinine, AST, ALT, LDH and platelets
|
72 hours after Ravulizumab infusion
|
Hospitalization length in the postpartum period
Time Frame: Approximately 3-5 days, it may vary
|
Length of hospital stay measured in number of days in hospital stay (peripartum period)
|
Approximately 3-5 days, it may vary
|
Meningococcal infection after use of ravulizumab
Time Frame: 72 hours up to 3 weeks after Ravulizumab infusion
|
Number of participants to present a meningococcal infection after use of Ravulizumab
|
72 hours up to 3 weeks after Ravulizumab infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Maria Lourdes Gonzalez Suarez, MD, PhD, Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
March 20, 2024
First Submitted That Met QC Criteria
March 20, 2024
First Posted (Actual)
March 27, 2024
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Pregnancy Complications
- Hypertension, Pregnancy-Induced
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Hypertension
- Pre-Eclampsia
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Complement Inactivating Agents
- Ravulizumab
Other Study ID Numbers
- 22-009239
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preeclampsia
-
MemorialCare Health SystemNot yet recruitingPreeclampsia | Preeclampsia Postpartum | Preeclampsia Severe | Preeclampsia Mild
-
Christiana Care Health ServicesActive, not recruitingPre-Eclampsia | Preeclampsia | Preterm | Preeclampsia Severe | Preeclampsia Second Trimester | Preeclampsia Complicating Childbirth | Preeclampsia PuerperiumUnited States
-
University Medical Centre LjubljanaCompletedPreeclampsia Postpartum | Preeclampsia SevereSlovenia
-
Cedars-Sinai Medical CenterThermoFisher Scientific Brahms Biomarkers FranceCompletedGestational Hypertension | Preeclampsia Severe | Preeclampsia and Eclampsia | Chronic Hypertension in Obstetric Context | Superimposed Pre-Eclampsia | Preeclampsia MildUnited States
-
Washington University School of MedicineRecruitingPreeclampsia Postpartum | Preeclampsia SevereUnited States
-
Brigham and Women's HospitalCompletedHypertension in Pregnancy | Postpartum | Postpartum Preeclampsia | Gestational Hypertension | Preeclampsia SevereUnited States
-
Christiana Care Health ServicesNot yet recruitingPreterm Birth Complication | Preeclampsia Severe | Preeclampsia Second TrimesterUnited States
-
AMAG Pharmaceuticals, Inc.TerminatedSevere PreeclampsiaUnited States, Poland, South Africa
-
Mpilo Central HospitalCompletedSevere PreeclampsiaZimbabwe
Clinical Trials on Ravulizumab
-
Alexion Pharmaceuticals, Inc.CompletedParoxysmal Nocturnal HemoglobinuriaItaly, Spain, Belgium, France, Turkey, Austria, Brazil, Netherlands, Australia, Finland, Russian Federation, Sweden, Canada, United States
-
BioCryst PharmaceuticalsTerminatedBCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)Paroxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, Hungary, France, Italy, Spain
-
Brigham and Women's HospitalActive, not recruiting
-
Alexion Pharmaceuticals, Inc.CompletedAtypical Hemolytic Uremic Syndrome (aHUS)United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
-
Alexion Pharmaceuticals, Inc.CompletedHealthyUnited Kingdom
-
Alexion PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria | PNHKorea, Republic of, Canada, France, Germany, Spain, Taiwan, United Kingdom
-
Alexion Pharmaceuticals, Inc.RecruitingChronic Kidney Disease | CKD | Cardiopulmonary Bypass | Cardiac DiseaseUnited States, China, Germany, Italy, Korea, Republic of, Spain, Japan, Brazil, India, Taiwan, Australia, Israel, Hong Kong, United Kingdom, Poland, Argentina, Canada, Turkey, Netherlands
-
Alexion Pharmaceuticals, Inc.RecruitingParoxysmal Nocturnal HemoglobinuriaItaly
-
AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
-
Alexion Pharmaceuticals, Inc.CompletedAtypical Hemolytic Uremic Syndrome (aHUS)Italy, United States, Korea, Republic of, Spain, Germany, Belgium, United Kingdom